Case Study

Due diligence on vascular graft technology

Our client was looking at potentially licensing some intellectual property and core technology around the bio-printing of vascular grafts. Before making the acquisition Werfen wanted to understand the risks involved with such a novel regenerative medicine technology. They came to Team to carry out a detailed review of the product, the IP and the feasibility of manufacturing scalability.

We reviewed all key aspects of graft function and process including material preparation, graft formation, sterilisation, system design, maintenance and quality control. We identified the key risks (both cause and effect) and potential risk mitigation actions. We also analysed the various scenarios determined by potential IP ownership and competitive technical know-how.

On considering our analysis they decided to not go ahead with licensing the technology.